RE:RE:BARDA and Project NextgenJavaman, you have a lot more faith than I regarding RFK'S
appointment or not as Trump's health czar.We shall see as the story unfolds.
As a past investor in IMV,I am familiar with the compelling science behind DPX tachnology.I had hoped Merck would take a stake in the Company prior to their bankrupcy but it did not happen.the inability of IMV's management to execute led to their eventual failure.
I would liked to have seen a larger phama buy out the Company. BIOV will need considerable funds to finalize clinical studies and with SP hovering around 7 cents raising funds thru bought deals or otherwise will not be sufficient.Funding support from BARDA would be a great help as well as partnerships.
I am impressed with the progress to date that BIOV has made and their transperancy with shareholders on their impressive and agressive progress.I started a position in BIOV when they bought out IMV and plan to increase it as developments occur.The DPX technology has the potential to greatly improve so msny areas of both animal and human health.Looking forward to a profitable 2025 with BIOV But with the understanding that it is a small junior with lots of obsticals to overcome,but they are on the right path for now.